metformin has been researched along with lysine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Audic, N; Ermolenko, L; Franck, G; Garcia-Alvarez, MC; Martin, MT; Nhiri, N; Potier, P; Sasaki, NA; Wang, Q | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Machado, AP; Moysés, ZP; Nakandakare, ER; Passarelli, M; Pinto, RS; Quintão, EC | 1 |
| Altshuler, D; Dabelea, D; Florez, JC; Franks, PW; Hamman, RF; Jablonski, KA; Kahn, SE; Knowler, WC; Nathan, DM | 1 |
| Chang, T; Desai, K; Jia, X; Wang, X; Wu, L | 1 |
| Barter, PJ; Brown, BE; Davies, MJ; Nobécourt, E; Rye, KA; Yadav, S; Zeng, J | 1 |
| Arakaki, RF; Florez, JC; Goldstein, BJ; Hanson, RL; Jablonski, KA; Kahn, SE; Kitabchi, AE; Knowler, WC; Mason, CC; McAteer, JB; Moore, AF | 1 |
| Bao, Y; Jia, W; Qiu, Y; Su, M; Wang, X; Zhao, T | 1 |
| Kanazawa, I; Sugimoto, T; Yamaguchi, T; Yamamoto, M | 1 |
| Lee, JA; Li, YC; Shih, YM | 1 |
| Chen, SM; Huang, TC; Lee, JA; Li, YC | 1 |
| Poretsky, L; Striker, GE; Vlassara, H; Woodward, M; Yubero-Serrano, EM | 1 |
| Berriche, O; Bouzidi, H; Haddad, M; Hammami, M; Kerkeni, M; Knani, I | 1 |
| Grillari, J; Khorsandi, L; Nayeri Rad, A; Safdarian, M; Shams, G; Sharif Makhmalzadeh, B | 1 |
| Ahmad, S; Alenazi, F; Alharbi, MS; Ashraf, JM; Hagbani, TA; Khaja, ASS; Qamar, M; Rafi, Z; Saleem, M; Zafar, M | 1 |
4 trial(s) available for metformin and lysine
| Article | Year |
|---|---|
Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program.
Topics: Alleles; ATP-Binding Cassette Transporters; Diabetes Mellitus, Type 2; Disease Progression; Female; Genetic Predisposition to Disease; Genotype; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lysine; Male; Metformin; Middle Aged; Mutation, Missense; Polymorphism, Genetic; Potassium Channels; Potassium Channels, Inwardly Rectifying; Proportional Hazards Models; Receptors, Drug; Sulfonylurea Receptors; Treatment Outcome | 2007 |
The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program.
Topics: Chromans; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Gene Frequency; Genetic Linkage; Genetic Predisposition to Disease; Glutamic Acid; Humans; Hypoglycemic Agents; Incidence; Lysine; Male; Metformin; Middle Aged; Phosphoric Diester Hydrolases; Polymorphism, Single Nucleotide; Pyrophosphatases; Risk Reduction Behavior; Thiazolidinediones; Troglitazone | 2009 |
Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus.
Topics: Aged; Arginine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Lysine; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Time Factors | 2011 |
Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease.
Topics: Adiponectin; Age Factors; Aged; Albuminuria; Chelating Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Estrogen Receptor alpha; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Lysine; Male; Metformin; Middle Aged; NF-E2-Related Factor 2; Pyruvaldehyde; Receptor for Advanced Glycation End Products; Receptors, Tumor Necrosis Factor, Type I; RNA, Messenger; Sevelamer; Sex Factors; Single-Blind Method; Sirtuin 1; White People | 2015 |
11 other study(ies) available for metformin and lysine
| Article | Year |
|---|---|
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
Topics: beta-Alanine; Chromatography, High Pressure Liquid; Electrophoresis, Polyacrylamide Gel; Glycation End Products, Advanced; Magnetic Resonance Spectroscopy; Peptides; Pyruvaldehyde | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products.
Topics: Albumins; Animals; Atherosclerosis; Cells, Cultured; Cholesterol, HDL; Diabetes Mellitus; Enzyme Inhibitors; Glycation End Products, Advanced; Guanidines; Humans; Hypoglycemic Agents; Lysine; Macrophages, Peritoneal; Metformin; Mice | 2006 |
Attenuation of hypertension development by scavenging methylglyoxal in fructose-treated rats.
Topics: Animals; Aorta; Dietary Carbohydrates; Fructose; Glutathione; Glycation End Products, Advanced; Hydrogen Peroxide; Hypertension; Hypoglycemic Agents; Lysine; Male; Mesenteric Arteries; Metformin; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Pyruvaldehyde; Rats; Rats, Sprague-Dawley | 2008 |
Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.
Topics: Apolipoprotein A-I; Arginine; Cross-Linking Reagents; Glycosylation; Guanidines; Humans; Lipoproteins, HDL; Lysine; Metformin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyridoxamine; Pyruvaldehyde; Thiazoles; Tryptophan | 2008 |
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.
Topics: Carbamates; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Agents; Lactic Acid; Lysine; Metabolomics; Metformin; Piperidines; Rosiglitazone; Thiazolidinediones; Uric Acid; Valine | 2009 |
Gentamicin caused renal injury deeply related to methylglyoxal and N(ɛ)-(carboxyethyl)lysine (CEL).
Topics: Animals; Anti-Bacterial Agents; Antioxidants; Gentamicins; Glutathione; Immunohistochemistry; Kidney Diseases; Kidney Function Tests; Lysine; Male; Metformin; Pyruvaldehyde; Rats; Rats, Wistar | 2013 |
Increased renal semicarbazide-sensitive amine oxidase activity and methylglyoxal levels in aristolochic acid-induced nephrotoxicity.
Topics: Amine Oxidase (Copper-Containing); Animals; Aristolochic Acids; Dose-Response Relationship, Drug; Kidney; Kidney Diseases; Lysine; Male; Metformin; Mice; Mice, Inbred C57BL; Pyruvaldehyde | 2014 |
Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
Topics: Adult; Arginine; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Lysine; Male; Metabolic Syndrome; Metformin; Middle Aged; Prognosis; Receptor for Advanced Glycation End Products | 2016 |
Metformin loaded cholesterol-lysine conjugate nanoparticles: A novel approach for protecting HDFs against UVB-induced senescence.
Topics: Animals; Cholesterol; Drug Carriers; Lysine; Metformin; Mice; Nanoparticles; Particle Size; Skin Absorption | 2020 |
Metformin encapsulated gold nanoparticles (MTF-GNPs): A promising antiglycation agent.
Topics: Arginine; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Gold; Humans; Hypoglycemic Agents; Lysine; Metal Nanoparticles; Metformin; Ribose; Serum Albumin, Bovine | 2022 |